Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- cit R-270 416 PAD-1 2 CC2565 NHACC NHACC2565 post-mortem
- Product Overview:
Citrullinated glial fibrillary acidic protein (citGFAP) is a citrullinated form of GFAP (Item No. 27353), a class III intermediate filament (IF) protein that is expressed in mature astrocytes and contributes to cytoskeletal structure and strength.{53009} GFAP can be citrullinated in a calcium-dependent manner on the arginine residue at position 270 (R270) and at R416 by protein arginine deiminase 1 (PAD1; Item No. 10784) and PAD2 (Item No. 10785).{53021} citGFAP levels are increased by the calcium ionophore ionomycin (Item No. 10004974) in an in vitro model of traumatic brain injury (TBI) using NHA CC-2565 human astrocytes and are induced by controlled cortical impact in the cerebral cortex in a rat model of TBI.{53020} It has been found in the hippocampus in a rat model of Alzheimer’s disease induced by amyloid-? (25-35), as well as in the retina in a mouse model of alkali-induced eye injury.{45561,45562} citGFAP has also been found in postmortem hippocampus from patients with Alzheimer’s disease, and citGFAP levels are increased in postmortem-derived brain lesions from patients with multiple sclerosis.{53021,35771} Cayman’s Citrullinated GFAP protein can be used for Western blot and ELISA applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.